‘Quick, nice, great': 5 cancer patients test Hong Kong-made ‘living drug'
Retiree Li Chun underwent various treatments for lymphoma for nine years before a new 'living drug' produced in Hong Kong finally made a difference.
Advertisement
The cancerous tumours she had lived with for so long began clearing up after she received treatment under a
Chinese University of Hong Kong (CUHK) clinical trial last October.
A big, painful tumour on her thigh was gone within a week. No active
cancer cells showed up in her body scan done in mid February.
'I don't feel much pain and don't have many problems,' the 73-year-old said, referring to the treatment. 'Three words to describe it – quick, nice, great.'
She was among the first five
Hong Kong cancer patients to undergo the clinical trial using locally manufactured chimeric antigen receptor T-cell (CAR-T) products.
Advertisement
The others are a girl, five, a boy, 15, a man, 67, and a woman, 71. All are doing well and four were discharged from hospital two to four weeks after receiving the CAR-T infusion.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTHK
19-05-2025
- RTHK
CUHK study finds mainland cancer drug to be effective
CUHK study finds mainland cancer drug to be effective CUHK researchers say the drug D3S-001 has shown promise during a phase 1 trial. Photo: RTHK Chinese University medical researchers on Monday said a multinational study they led has found a mainland-developed cancer drug to be effective in treating tumours. They said the drug D3S-001, from company D3Bio, has shown promise during a phase 1 trial involving patients with cancers of the lung, pancreas and colon that are driven by KRAS-G12C gene mutations. More than 70 percent of those who took part in the trial saw their tumours shrink significantly or disappear altogether, the researchers said. Associate professor at the university's department of clinical oncology, Dr Herbert Loong, said the new drug is more effective than previous treatments. "In the sense that it does inhibit KRAS-G12C at a quicker rate and most likely at a longer duration as well," Loong said. Professor Tony Mok, who chairs the department, said further study is needed. "We are actually looking into a phase three development, most likely we would like to see this compound as a first-line medication," Mok said. The researchers said their findings have been published in the Nature Medicine journal.
South China Morning Post
19-05-2025
- South China Morning Post
Mainland Chinese drug effective in treating 3 cancer types: Hong Kong-led study
A new drug developed by a mainland Chinese biotechnology company is effective in combating three types of cancer that currently have limited treatment options, a multinational study led by the Chinese University of Hong Kong (CUHK) has found. University researchers said on Monday that the novel drug, D3S-001, can treat non-small-cell lung, colorectal, and pancreatic cancers triggered by the gene mutation KRAS-G12C. The drug is said to be a 'next-generation' inhibitor for the gene mutation, which can currently only be treated using a limited number of therapeutic options. 'It does inhibit KRAS-G12C at a quicker rate and most likely at a longer duration as well [compared with a first-generation inhibitor],' said Dr Herbert Loong Ho-fung, an associate professor at CU Medicine's clinical oncology department. 'This is demonstrated in the laboratory and certainly in our clinical trials. We're also seeing signals of this in our patients.' Loong said phase one of the drug's clinical trial found that 70 per cent of the 42 participating patients who received the inhibitor for the first time saw a significant shrinkage or disappearance of their tumours.
HKFP
15-05-2025
- HKFP
Almost one-third of LGBTQ-identifying people report symptoms of moderate to severe depression, survey finds
Almost one-third of people identifying as LGBTQ in Hong Kong reported symptoms of moderate to severe depression, a study has found, with some saying they were treated poorly because of their sexual identity when seeking help. LGBTQ non-profit Society of True Light, together with professors from the Chinese University of Hong Kong (CUHK) and the University of Hong Kong (HKU), announced on Wednesday the results of a survey on mental health in the LGBTQ community. The study, which surveyed 1,433 people, found that 30.8 per cent of respondents reported symptoms of moderate to severe depression, while 24 per cent reported symptoms of moderate to severe anxiety. A survey conducted in 2017 found that 30.9 per cent of respondents reported symptoms of moderate to severe depression, while 25.9 per cent reported symptoms of moderate to severe anxiety. 'The comparison with figures seven years ago shows that these mental health indicators have not improved, revealing a long-neglected mental health issue that urgently requires comprehensive responses at the societal and policy levels,' said Randolph Chan, an associate professor at the CUHK's Department of Social Work. Among the 1,433 people surveyed for the latest study, 783 identified as gay or lesbian, 457 as bisexual or pansexual, 177 identified as 'others,' and 16 as heterosexual. The average age of respondents was 29.2. The survey results, released ahead of International Day Against Homophobia, Biphobia and Transphobia (IDAHOT) on Saturday, also showed that some respondents reported negative experiences when seeking mental health help. Of those who disclosed they had sought mental health help, 15.8 per cent said they were told that their sexual identity was a result of childhood trauma or family problems. Around 10 per cent reported being told to 'straighten' themselves, or to change their sexual orientation and become heterosexual. 'Service gap' Speaking at the press conference on Wednesday, activists said there was a lack of mental health support for the LGBTQ community. Colby Li, a registered social worker who works with gay men, said many social services require government funding, and the government tended to emphasise certain public health issues, such as drug addiction or HIV diagnoses. 'Yes, there is a need for that, but on the other side, we see a service gap,' Li said in Cantonese. 'There are a lot of gay men whose struggles are not related to drugs or HIV,' he said, adding that some were burdened by issues that could cause stress, like financial or relationship problems. When the government's policy places too much emphasis on certain public health issues, 'there is little general mental health support in society for gay men or others in the LGBTQ community,' Li said. Ming Chan, a doctor and one of the founders of Quarks, an NGO supporting transgender youth, said transgender youth face more challenges than their older peers. Young people who are undergoing puberty 'have a lot of changes in the body and are also exploring their identity,' said Chan, who is also a transgender woman. 'Their gender dysphoria might be stronger… but they don't have a lot of resources around them.' Transgender youth also face additional obstacles in accessing mental health support as they are financially reliant on their family. They may also have to involve their parents or schools if they want to seek help, she added.
